Wall Street analysts expect Marinus Pharmaceuticals Inc (NASDAQ:MRNS) to announce ($0.23) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Marinus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.26). Marinus Pharmaceuticals reported earnings per share of ($0.24) during the same quarter last year, which would suggest a positive year-over-year growth rate of 4.2%. The company is expected to announce its next quarterly earnings report on Thursday, August 1st.
According to Zacks, analysts expect that Marinus Pharmaceuticals will report full-year earnings of ($0.86) per share for the current fiscal year, with EPS estimates ranging from ($1.04) to ($0.55). For the next financial year, analysts forecast that the business will post earnings of ($0.86) per share, with EPS estimates ranging from ($1.25) to ($0.24). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Marinus Pharmaceuticals.
Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.03).
In other news, CFO Edward F. Smith sold 24,211 shares of Marinus Pharmaceuticals stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $5.03, for a total transaction of $121,781.33. Following the sale, the chief financial officer now directly owns 20,097 shares in the company, valued at approximately $101,087.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.10% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Two Sigma Advisers LP bought a new stake in shares of Marinus Pharmaceuticals during the 4th quarter worth $146,000. Bailard Inc. purchased a new stake in Marinus Pharmaceuticals in the 1st quarter worth about $138,000. Tekla Capital Management LLC increased its holdings in Marinus Pharmaceuticals by 124.8% in the 4th quarter. Tekla Capital Management LLC now owns 755,776 shares of the biopharmaceutical company’s stock worth $2,169,000 after acquiring an additional 419,548 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Marinus Pharmaceuticals in the 4th quarter worth about $69,000. Finally, 683 Capital Management LLC increased its holdings in Marinus Pharmaceuticals by 22.7% in the 4th quarter. 683 Capital Management LLC now owns 1,350,000 shares of the biopharmaceutical company’s stock worth $3,875,000 after acquiring an additional 250,000 shares during the last quarter. Institutional investors own 63.35% of the company’s stock.
NASDAQ:MRNS opened at $3.67 on Wednesday. The stock’s 50-day simple moving average is $4.33. The company has a market cap of $200.78 million, a P/E ratio of -4.08 and a beta of 3.16. Marinus Pharmaceuticals has a 52 week low of $2.36 and a 52 week high of $10.54.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Recommended Story: What moving averages are used to define a golden cross?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.